Abstracts tagged "APL and antibodies"

Abstract Number: 1 • 2013 ACR/ARHP Annual Meeting
Anti-â2GP1- Domain-1 Antibodies Are a Marker Of APS Severity
Nancy Agmon-Levin¹, Luciana Seguro², Cristina Rosário³, Michael Mahler⁴, Mariele Gatto⁵, Nir Tomer⁶, Elaine P. Leon⁷, Andrea Doria⁸, László Kovács⁹, Nathalie Costedoat-Chalumeau¹⁰, Boris Gilburd¹¹ and Yehuda Shoenfeld¹², ¹The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Israel, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Internal Medicine Department, Hospital de Pedro Hispano, Rua Dr. Eduardo Torres Matosinhos, Porto, Portugal, ⁴Research, INOVA Diagnostics, San Diego, CA, ⁵Department of Medicine-DIMED, University of Padova, Padova, Italy, ⁶The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, ⁷Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁸Division of Rheumatology, University of Padova, Padova, Italy, ⁹Department of Rheumatology, University of Szeged, Szeged, Hungary, ¹⁰Internal Medicine, Hopital Cochin, Paris, France, ¹¹The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, ¹²The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Autoantibodies targeting Domain-1(D1) of beta-2-glycoprotein-1(β2GP1) are common among patients with the antiphospholipid syndrome (APS)1. However, few studies assessed their clinical relevance and correlation with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].